News

DDN goes with Axway’s Trade Activity Manager; repackager Apace Packaging chooses Supplyscape’s Nexus platform

American Recovery and Reinvestment Act allocates $18 billion for HIT

Drugmakers face difficulty justifying expenses amid restrictions

Bipartisan group of senators sponsor a revived drug-importation bill

Although human trials in the U.S. are still a novelty, developers are identifying both sources and protocols for conducting therapy

Regulatory attention has intensified over commercial activities. Here’s what to do to minimize risks and raise compliance levels

The studio model: how film industry practices can boost pharmaceutical creativity

While track-and-trace initiatives stumble along, more technology firms provide authentication solutions

Referencing in pharmaceutical compendia and peer-reviewed literature are a guide

Dispensed prescription volume grew 0.9%

Program appears to improve medication adherence and decrease therapeutic duplications

Expect a flood of product-liability suits in the aftermath of Wyeth vs. Levine

While California’s e-pedigree initiative sits on a shelf, actions in Washington and Brussels point to renewed efforts for track-and-trace of pharmaceuticals

Seattle nonprofit’s implementation highlights role of pharmacist in patient care

Opioid abuse detected by program that may be useful in REMS and post-market surveillance

Although beset by less-than-friendly federal reimbursement policies, independent pharmacies are maintaining their viability for pharmaceutical delivery

Biopharmaceutical manufacturers turn to a direct-distribution model to leverage opportunities for cost-effective drug delivery and personalized health management services

Alleged mishandling of discarded patient records call the giant retailer’s privacy safeguards into question

The high-tech mecca plans to maintain its status as an economic driver for North Carolina

Nemours plans campus for pediatric treatment and research

Stable economics and growing healthcare concerns make Brazil one of the top emerging markets, with a current growth rate >20%

Multiplying state laws on marketing and distribution disclosures might be pre-empted by new federal legislation

McKesson is a heavy hitter in the category, says Kalorama Information

Higher complexity—and expense—are the reality for most drug research, says Tufts

Higher co-pays, ‘NDC block policies’ and multiple tiers add to drug benefit complexity

Dataset has ‘exclusive’ source, the ArcLight consortium

Program combines retail pharmacy, in-store and onsite clinics for employer health plans